Genentech persevERA breast cancer trial misses PFS goal
03/09/2026 –…
Roche persevERA breast cancer trial misses goal
Roche (OTCQX: RHHBY) reported that the phase III persevERA study of giredestrant plus palbociclib in 1L ER+/HER2- advanced…
Roche’s Setback: Giredestrant Fails in Key Breast Cancer Trial
Shares in Roche tumbled Monday, dropping more than 5%, as the Swiss pharmaceutical giant faced disappointment with…
Roche Stock Falls as Breast Cancer Drug Fails Trial Goals
In a significant setback, Roche’s shares suffered a steep drop exceeding 7% at one point on Monday…
Roche’s Cancer Drug Setback: Stocks Tumble
Roche’s stocks took a hit on Monday, dropping over 5%, as their breast cancer drug candidate, giredestrant,…
Roche oral drug shown to keep breast cancer at bay, boosting shares
Roche oral drug shown to keep breast cancer at bay, boosting shares Roche’s experimental oral drug giredestrant has been…
Roche giredestrant NDA accepted by FDA for breast cancer
Roche (OTCQX: RHHBY) announced FDA acceptance of its New Drug Application for giredestrant…
CERAN wrap: Roche phase III BC win seals thesis, boosts Olema
Roche AG’s Genentech unit landed another clinical victory with giredestrant that provided a major stock boost for competitor…
Roche oral SERD giredestrant boosts iDFS in early breast cancer
Roche (OTCQX: RHHBY) reported positive Phase III results from the lidERA trial of…
Roche’s giredestrant cuts recurrence, death risk 30% in early breast cancer
Roche (OTCQX: RHHBY) announced positive phase III lidERA results showing investigational oral SERD…
Giredestrant demonstrates efficacy in early-stage breast cancer
Roche has reported positive Phase III data for its selective estrogen receptor degrader (SERD) giredestrant across multiple stages…